Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45


Study of hepatitis E virus ORF2 antigen kinetics in human-liver chimeric mice and its impact on HEV diagnosis.

Sayed IM, Verhoye L, Montpellier C, Abravanel F, Izopet J, Cocquerel L, Meuleman P.

J Infect Dis. 2019 Apr 18. pii: jiz171. doi: 10.1093/infdis/jiz171. [Epub ahead of print]


New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle.

Ankavay M, Montpellier C, Sayed IM, Saliou JM, Wychowski C, Saas L, Duvet S, Aliouat-Denis CM, Farhat R, de Masson d'Autume V, Meuleman P, Dubuisson J, Cocquerel L.

Sci Rep. 2019 Apr 18;9(1):6243. doi: 10.1038/s41598-019-42737-2.


[The hepatitis E virus, an unknown virus that reveals itself].

Ankavay M, Dubuisson J, Cocquerel L.

Med Sci (Paris). 2018 Dec;34(12):1071-1078. doi: 10.1051/medsci/2018299. Epub 2019 Jan 9. Review. French.


Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses.

Ferlin J, Farhat R, Belouzard S, Cocquerel L, Bertin A, Hober D, Dubuisson J, Rouillé Y.

J Gen Virol. 2018 Aug;99(8):1086-1096. doi: 10.1099/jgv.0.001099. Epub 2018 Jun 20.


Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.

Riva L, Song OR, Prentoe J, Helle F, L'homme L, Gattolliat CH, Vandeputte A, Fénéant L, Belouzard S, Baumert TF, Asselah T, Bukh J, Brodin P, Cocquerel L, Rouillé Y, Dubuisson J.

J Virol. 2018 Apr 27;92(10). pii: e01982-17. doi: 10.1128/JVI.01982-17. Print 2018 May 15.


Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication.

Farhat R, Ankavay M, Lebsir N, Gouttenoire J, Jackson CL, Wychowski C, Moradpour D, Dubuisson J, Rouillé Y, Cocquerel L.

Cell Microbiol. 2018 Jan;20(1). doi: 10.1111/cmi.12804. Epub 2017 Nov 17.


Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein.

Montpellier C, Wychowski C, Sayed IM, Meunier JC, Saliou JM, Ankavay M, Bull A, Pillez A, Abravanel F, Helle F, Brochot E, Drobecq H, Farhat R, Aliouat-Denis CM, Haddad JG, Izopet J, Meuleman P, Goffard A, Dubuisson J, Cocquerel L.

Gastroenterology. 2018 Jan;154(1):211-223.e8. doi: 10.1053/j.gastro.2017.09.020. Epub 2017 Sep 25.


Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.

Vausselin T, Séron K, Lavie M, Mesalam AA, Lemasson M, Belouzard S, Fénéant L, Danneels A, Rouillé Y, Cocquerel L, Foquet L, Rosenberg AR, Wychowski C, Meuleman P, Melnyk P, Dubuisson J.

J Virol. 2016 Sep 12;90(19):8422-34. doi: 10.1128/JVI.00404-16. Print 2016 Oct 1.


Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.

Sayed IM, Verhoye L, Cocquerel L, Abravanel F, Foquet L, Montpellier C, Debing Y, Farhoudi A, Wychowski C, Dubuisson J, Leroux-Roels G, Neyts J, Izopet J, Michiels T, Meuleman P.

Gut. 2017 May;66(5):920-929. doi: 10.1136/gutjnl-2015-311109. Epub 2016 Mar 22.


Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro.

Fénéant L, Ghosn J, Fouquet B, Helle F, Belouzard S, Vausselin T, Séron K, Delfraissy JF, Dubuisson J, Misrahi M, Cocquerel L.

PLoS One. 2015 Nov 12;10(11):e0142539. doi: 10.1371/journal.pone.0142539. eCollection 2015.


SRFBP1, an Additional Player in HCV Entry.

Fénéant L, Cocquerel L.

Trends Microbiol. 2015 Oct;23(10):590-593. doi: 10.1016/j.tim.2015.08.003. Epub 2015 Aug 26.


New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.

Fénéant L, Potel J, François C, Sané F, Douam F, Belouzard S, Calland N, Vausselin T, Rouillé Y, Descamps V, Baumert TF, Duverlie G, Lavillette D, Hober D, Dubuisson J, Wychowski C, Cocquerel L.

J Virol. 2015 Aug;89(16):8346-64. doi: 10.1128/JVI.00192-15. Epub 2015 Jun 3.


Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.

Al Olaby RR, Cocquerel L, Zemla A, Saas L, Dubuisson J, Vielmetter J, Marcotrigiano J, Khan AG, Vences Catalan F, Perryman AL, Freundlich JS, Forli S, Levy S, Balhorn R, Azzazy HM.

PLoS One. 2014 Oct 30;9(10):e111333. doi: 10.1371/journal.pone.0111333. eCollection 2014.


CD81 and hepatitis C virus (HCV) infection.

Fénéant L, Levy S, Cocquerel L.

Viruses. 2014 Feb 6;6(2):535-72. doi: 10.3390/v6020535. Review.


EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry.

Potel J, Rassam P, Montpellier C, Kaestner L, Werkmeister E, Tews BA, Couturier C, Popescu CI, Baumert TF, Rubinstein E, Dubuisson J, Milhiet PE, Cocquerel L.

Cell Microbiol. 2013 Jul;15(7):1234-52. doi: 10.1111/cmi.12112. Epub 2013 Feb 16.


The antimalarial ferroquine is an inhibitor of hepatitis C virus.

Vausselin T, Calland N, Belouzard S, Descamps V, Douam F, Helle F, François C, Lavillette D, Duverlie G, Wahid A, Fénéant L, Cocquerel L, Guérardel Y, Wychowski C, Biot C, Dubuisson J.

Hepatology. 2013 Jul;58(1):86-97. doi: 10.1002/hep.26273. Epub 2013 May 14.


Structural basis of ligand interactions of the large extracellular domain of tetraspanin CD81.

Rajesh S, Sridhar P, Tews BA, Fénéant L, Cocquerel L, Ward DG, Berditchevski F, Overduin M.

J Virol. 2012 Sep;86(18):9606-16. doi: 10.1128/JVI.00559-12. Epub 2012 Jun 27.


Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies.

Delavalle PY, Alsaleh K, Pillez A, Cocquerel L, Allet C, Dumont P, Loyens A, Leteurtre E, Omary MB, Dubuisson J, Rouillé Y, Wychowski C.

Exp Cell Res. 2011 Nov 1;317(18):2683-94. doi: 10.1016/j.yexcr.2011.08.018. Epub 2011 Aug 31.


Interacting regions of CD81 and two of its partners, EWI-2 and EWI-2wint, and their effect on hepatitis C virus infection.

Montpellier C, Tews BA, Poitrimole J, Rocha-Perugini V, D'Arienzo V, Potel J, Zhang XA, Rubinstein E, Dubuisson J, Cocquerel L.

J Biol Chem. 2011 Apr 22;286(16):13954-65. doi: 10.1074/jbc.M111.220103. Epub 2011 Feb 22.


HCV research 20 years after discovery: a summary of the 16th international symposium on hepatitis C virus and related viruses.

Pawlotsky JM, Cocquerel L, Durantel D, Lavillette D, Lerat H, Pécheur EI, Polyak SJ, Tautz N, Thimme R.

Gastroenterology. 2010 Jan;138(1):6-12.e1-2. doi: 10.1053/j.gastro.2009.11.018. Epub 2009 Nov 18. No abstract available.


The Ig domain protein CD9P-1 down-regulates CD81 ability to support Plasmodium yoelii infection.

Charrin S, Yalaoui S, Bartosch B, Cocquerel L, Franetich JF, Boucheix C, Mazier D, Rubinstein E, Silvie O.

J Biol Chem. 2009 Nov 13;284(46):31572-8. doi: 10.1074/jbc.M109.057927. Epub 2009 Sep 17.


[Occludin, an additional key for hepatitis C virus entry].

Tews BA, Cocquerel L.

Med Sci (Paris). 2009 Jun-Jul;25(6-7):549-51. doi: 10.1051/medsci/2009256-7549. French. No abstract available.


The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry.

Rocha-Perugini V, Lavie M, Delgrange D, Canton J, Pillez A, Potel J, Lecoeur C, Rubinstein E, Dubuisson J, Wychowski C, Cocquerel L.

BMC Microbiol. 2009 May 28;9:111. doi: 10.1186/1471-2180-9-111.


The CD81 partner EWI-2wint inhibits hepatitis C virus entry.

Rocha-Perugini V, Montpellier C, Delgrange D, Wychowski C, Helle F, Pillez A, Drobecq H, Le Naour F, Charrin S, Levy S, Rubinstein E, Dubuisson J, Cocquerel L.

PLoS One. 2008 Apr 2;3(4):e1866. doi: 10.1371/journal.pone.0001866.


Early steps of the hepatitis C virus life cycle.

Dubuisson J, Helle F, Cocquerel L.

Cell Microbiol. 2008 Apr;10(4):821-7. Epub 2007 Dec 13. Review.


Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry.

Voisset C, Lavie M, Helle F, Op De Beeck A, Bilheu A, Bertrand-Michel J, Tercé F, Cocquerel L, Wychowski C, Vu-Dac N, Dubuisson J.

Cell Microbiol. 2008 Mar;10(3):606-17. Epub 2007 Nov 2.


Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins.

Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouillé Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C.

J Gen Virol. 2007 Sep;88(Pt 9):2495-503.


Hepatitis C virus entry: potential receptors and their biological functions.

Cocquerel L, Voisset C, Dubuisson J.

J Gen Virol. 2006 May;87(Pt 5):1075-84. Review.


Kinetics of HCV envelope proteins' interaction with CD81 large extracellular loop.

Nakajima H, Cocquerel L, Kiyokawa N, Fujimoto J, Levy S.

Biochem Biophys Res Commun. 2005 Mar 25;328(4):1091-100.


Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions.

Carrère-Kremer S, Montpellier C, Lorenzo L, Brulin B, Cocquerel L, Belouzard S, Penin F, Dubuisson J.

J Biol Chem. 2004 Oct 1;279(40):41384-92. Epub 2004 Jul 7.


Characterization of functional hepatitis C virus envelope glycoproteins.

Op De Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z, Foung S, Cosset FL, Dubuisson J.

J Virol. 2004 Mar;78(6):2994-3002.


CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Cocquerel L, Kuo CC, Dubuisson J, Levy S.

J Virol. 2003 Oct;77(19):10677-83.


Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody.

Cocquerel L, Quinn ER, Flint M, Hadlock KG, Foung SK, Levy S.

J Virol. 2003 Jan;77(2):1604-9.


Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins.

Cocquerel L, Op de Beeck A, Lambot M, Roussel J, Delgrange D, Pillez A, Wychowski C, Penin F, Dubuisson J.

EMBO J. 2002 Jun 17;21(12):2893-902.


Subcellular localization and topology of the p7 polypeptide of hepatitis C virus.

Carrère-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, Dubuisson J.

J Virol. 2002 Apr;76(8):3720-30.


Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line.

Duvet S, Op De Beeck A, Cocquerel L, Wychowski C, Cacan R, Dubuisson J.

Glycobiology. 2002 Feb;12(2):95-101.


Biogenesis of hepatitis C virus envelope glycoproteins.

Op De Beeck A, Cocquerel L, Dubuisson J.

J Gen Virol. 2001 Nov;82(Pt 11):2589-95. Review. No abstract available.


Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2.

Cocquerel L, Meunier JC, Op de Beeck A, Bonte D, Wychowski C, Dubuisson J.

J Gen Virol. 2001 Jul;82(Pt 7):1629-35.


Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein.

Dubuisson J, Duvet S, Meunier JC, Op De Beeck A, Cacan R, Wychowski C, Cocquerel L.

J Biol Chem. 2000 Sep 29;275(39):30605-9.


The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization.

Op De Beeck A, Montserret R, Duvet S, Cocquerel L, Cacan R, Barberot B, Le Maire M, Penin F, Dubuisson J.

J Biol Chem. 2000 Oct 6;275(40):31428-37.


Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex.

Meunier JC, Fournillier A, Choukhi A, Cahour A, Cocquerel L, Dubuisson J, Wychowski C.

J Gen Virol. 1999 Apr;80 ( Pt 4):887-96.


The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum.

Cocquerel L, Duvet S, Meunier JC, Pillez A, Cacan R, Wychowski C, Dubuisson J.

J Virol. 1999 Apr;73(4):2641-9.


Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval.

Duvet S, Cocquerel L, Pillez A, Cacan R, Verbert A, Moradpour D, Wychowski C, Dubuisson J.

J Biol Chem. 1998 Nov 27;273(48):32088-95.


Supplemental Content

Loading ...
Support Center